Osteoporotic vertebral compression fractures (OVCFs) are the most common osteoporotic fractures. Pain is the main symptom. Percutaneous vertebroplasty (PVP) is a therapeutic procedure performed to reduce pain in vertebral compression fractures. Numerous case series and several small, non-blinded, non-randomized controlled studies have suggested that vertebroplasty is an effective means of relieving pain from osteoporotic fractures. However, a recent pooled analysis from 2 multicenter randomized controlled trials concluded that the improvement in pain afforded by PVP was similar to placebo.

Objective: To compare the amount of pain reduction measured using the visual analog scale when OVCF is treated with vertebroplasty or conservatively, and assess the clinical utility of PVP.

Design: A meta-analysis and systematic review of randomized controlled trials was performed comparing pain reduction following vertebroplasty and conservative treatment.

Limitations: There were few data sources from which to extract abstracted data or published studies. There were only 5 randomized controlled trials that met our criteria. The conservative treatments used as comparators in these trials were different.

Methods: A search of MEDLINE from January 1980 to July 2012 using PubMed, the Cochrane Database of Systematic Reviews and Controlled Trials, CINAHL, and EMBASE. Relevant reports were examined by 2 independent reviewers and the references from these reports were searched for additional trials, using the criteria established in the QUOROM statement.

Results: Pooled results from 5 randomized controlled trials are shown. There was no difference in pain relief in the PVP group at 2 weeks and one month when compared with the conservatively managed group. Pain relief in the PVP group was greater than that of the conservative group at 3 months, 6 months, and 12 months. However, after subgroup analysis, pain scores were similar between the PVP group and the sham injection group from 2 weeks to 6 months. Compared with non-operative therapy, PVP reduced pain at all times studied.

Conclusion: PVP has some value for relieving pain; however, the possibility of a placebo effect should be considered. PVP has gained acceptance as a complementary treatment when conservative management has failed before its benefits have been fully understood. More large scale, double blinded, controlled trials are necessary in order to quantify the pain relief afforded by PVP more precisely.

Key words: Vertebroplasty, osteoporosis, vertebral compression fracture, randomized controlled trials, systemic review, meta-analysis
Osteoporotic vertebral compression fractures (OVCF) are a common cause of pain and disability and are associated with increased mortality (1). Patients with vertebral fractures can present with severe back pain lasting for weeks or months. Until recently, the mainstays of treatment were conservative: bed rest, analgesia, immobilization, and then physical therapy (2). Vertebroplasty, a procedure in which bone cement is injected percutaneously into the fractured vertebral body, was developed as an alternative option for the treatment of pain (3-5). Percutaneous vertebroplasty (PVP) is generally seen as a safe and effective procedure for painful OVCF (6-9). However, there is a body of opinion that the long-term analgesic effect of PVP for the treatment of acute and subacute fractures is not superior to conservative treatment, and that PVP should be only be offered to patients after conservative treatment has failed (10-12). The benefits compared with conservative treatment have not been evaluated until now.

The aim of this study was to compare the analgesic effects of PVP with conservative treatment of OVCF in a meta-analysis of randomized controlled trials. To achieve the aim we performed this systematic review. We searched a large quantity of relevant references and selected several publications in accordance with our requirements. Then we utilized the RevMan Version 5.0.2 software (The Cochrane Collaboration, England) to assess the risk of bias and finally determined 5 references for the meta-analysis. The subgroup analysis at various follow-up times was also performed.

Methods

Selection Criteria

All peer reviewed randomized controlled trials published in English up to July 2012 that compared vertebroplasty with conservative or sham treatments for OVCF and used the visual analog scale (VAS) as an objective measure of pain were identified and reviewed. Although there are many measures of pain, such as VAS, Numeric Rating Scale (NRS), McGill Pain Questionnaire (MPQ), Chronic Pain Grade Scale (CPGS), et al, most of publications use the VAS as an objective measure of pain. In order to unify the selection criteria, we chose the VAS as an objective measure of pain in this study.

Search Strategy

Two independent reviewers conducted a computerized search of MEDLINE using PubMed, the Cochrane Database of Systematic reviews, the Cochrane Central Register of Controlled Trials, CINAHL, and EMBASE to find relevant articles published between January 1980 and July 2012. The search terms used were “vertebroplasty AND compression fracture AND randomized control trial.”

Quality Assessment

Articles which met the selection criteria were assessed the quality using Review Manager (RevMan) software and the bias was determined using the Cochrane Risk of Bias table. The Cochrane Risk of Bias table includes 7 bias: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. Articles which were in accordance with 3 or more bias had high quality (13,14). We finally selected these articles with high quality for the meta-analysis.

Analysis Technique

Data analysis was conducted using RevMan Version 5.0.2 software provided by the Cochrane Collaboration. All analyses were carried out on an intention-to-treat basis; that is, all patients randomly assigned to a treatment group were included in the analyses according to the assigned treatment, irrespective of whether they received the treatment or were excluded from analysis by the investigators. For categorical variables, weighted risk ratios and their 95% confidence intervals (CI) were calculated using RevMan 5.0.2 software according to the Peto method. Results were tested for heterogeneity at a significance level of $P < 0.05$ according to the methods outlined. A fixed effects model was used if there was no evidence of heterogeneity between studies; if there was evidence of heterogeneity, a random effects model was used for the meta-analysis.

For trials reporting change from baseline values (15), the mean and standard deviation (SD) of final values was obtained by using the following formula (16), the correlation between baseline and final values ($r_{baseline, final}$) was assumed to be 0.5: $SD^2_{final} - 2r_{baseline, final} SD_{baseline} SD_{final}$.
Systematic reviews, the Cochrane Central Register of Controlled Trials, CINAHL, and EMBASE. Searching the inclusion criteria in title and abstract, we achieved 10 articles (3,12,15,17-23), and selected 6 articles by excluding 4 articles, among them, 3 articles were nonrandomized controlled trials (21-23) and one article was about percutaneous kyphoplasty (20).

The trial assessors selected 6 randomized controlled trials for further quality analysis and review (3,12,15,17-19). However, the study reported by Voormolen et al (19) was excluded as patients were allowed to cross over from the conservative group to the PVP group after 2 weeks of treatment and there was deemed to have been a high risk of bias. Thus 5 randomized controlled trials were used in the meta-analysis. The study selection process and reasons for exclusion are summarized in Fig. 1.

The 5 randomized controlled trials selected represented a total of 291 patients undergoing vertebroplasty and 286 patients managed conservatively. A list of the studies accepted for the meta-analysis is provided in Table 1. When the PVP groups are compared with

<table>
<thead>
<tr>
<th>Study Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>Buchbinder, 2009</td>
</tr>
<tr>
<td>Klazen, 2010</td>
</tr>
<tr>
<td>Farrokhi, 2011</td>
</tr>
<tr>
<td>Kallmes, 2009</td>
</tr>
<tr>
<td>Rousing, 2009</td>
</tr>
</tbody>
</table>

Table 1. Details of the studies included in the meta-analysis.

PVP: percutaneous vertebroplasty; OPT: optimum pain treatment; OMT: optimal medical therapy; CT: conservative treatment
the conservative treatment groups; no statistically significant differences in age or gender proportion were found (Table 1). The pain VAS data reported in each study are presented in Table 2.

Two reviewers independently assessed the methodological quality of the included trials with Review Manager software, assessing factors such as randomization, allocation concealment, whether baseline data were similar, blinding, blinding of outcome assessments, and selective reporting. The outcome is summarized in Fig. 2. There was a low risk of selection bias given the use of computerized random number generators and opaque sealed envelopes in all studies.

There were no differences in pain relief between the PVP and the conservative groups at 2 weeks and one month ($P = 0.14$ and 0.08 respectively, Figs. 3-4); however, PVP appeared to afford greater long-term pain relief at 2-3 months, 6 months, and 12 months ($P < 0.0001$, Figs. 5-7). A degree of heterogeneity was noted among the pain scores reported at different times. In a subgroup analysis, we divided the conservative group into a sham injection group (15,18) and a non-operative group (3,12,17). We found no difference in pain scores between the PVP and the sham injection groups at 2 weeks, one month, 3 months, or 6 months ($P =$ 0.65, 0.18, 0.63, and 1, respectively, Figs. 3-6). However, compared with non-operative therapy, the reduction in pain afforded by PVP was significantly greater than that of the non-operative group at 2 weeks, one month, 3 months, 6 months, and 12 months ($P < 0.0001$, Figs. 3-7).

**Discussion**

Our meta-analysis showed that there was no difference in pain relief between the PVP and the conservatively managed groups at 2 weeks and one month. Pain relief in the PVP group was superior to that of the conservative group at 3 months, 6 months, and 12 months. Pain scores were similar between the PVP and sham injection groups from 2 weeks to 6 months. When compared with non-operative therapy, PVP reduced pain at all times at which it was measured.

There were differences between the PVP group and the conservative group at different time points, which may be a consequence of the variety of conserva-

---

**Table 2. Visual analog pain scales (VAS) reported in the studies included in the meta-analysis**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PVP</td>
<td>Control</td>
<td>PVP</td>
<td>Control</td>
<td>PVP</td>
</tr>
<tr>
<td>Preop VAS</td>
<td>7.4 ± 2.1</td>
<td>7.1 ± 2.3</td>
<td>7.8 ± 1.5</td>
<td>7.5 ± 1.6</td>
<td>8.4 ± 1.6</td>
</tr>
<tr>
<td>N</td>
<td>38</td>
<td>40</td>
<td>101</td>
<td>101</td>
<td>40</td>
</tr>
<tr>
<td>1 w VAS</td>
<td>1.5 ± 2.5</td>
<td>2.1 ± 2.8</td>
<td>3.5 ± 2.5</td>
<td>5.6 ± 2.5</td>
<td>3.3 ± 1.5</td>
</tr>
<tr>
<td>N</td>
<td>37</td>
<td>37</td>
<td>97</td>
<td>93</td>
<td>40</td>
</tr>
<tr>
<td>2 w VAS</td>
<td>2.3 ± 2.6</td>
<td>1.7 ± 3.3</td>
<td>2.5 ± 2.5</td>
<td>4.9 ± 2.6</td>
<td>3.9 ± 2.9</td>
</tr>
<tr>
<td>N</td>
<td>35</td>
<td>38</td>
<td>96</td>
<td>92</td>
<td>67</td>
</tr>
<tr>
<td>1 m VAS</td>
<td>2.6 ± 2.9</td>
<td>1.9 ± 3.3</td>
<td>2.5 ± 2.7</td>
<td>3.9 ± 2.8</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>36</td>
<td>37</td>
<td>92</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>3 m VAS</td>
<td>2.4 ± 3.3</td>
<td>2.1 ± 3.3</td>
<td>2.3 ± 2.7</td>
<td>3.9 ± 2.9</td>
<td>2.2 ± 2.1</td>
</tr>
<tr>
<td>N</td>
<td>35</td>
<td>36</td>
<td>89</td>
<td>81</td>
<td>40</td>
</tr>
<tr>
<td>6 m VAS</td>
<td>2.2 ± 2.7</td>
<td>3.8 ± 2.8</td>
<td>2.2 ± 2.1</td>
<td>4.1 ± 1.8</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>86</td>
<td>77</td>
<td>38</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Notes VAS</td>
<td>Change Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>Mean (cl)</td>
<td>Mean ± SD</td>
</tr>
</tbody>
</table>

---

458 www.painphysicianjournal.com
Comparing Pain Reduction Following Vertebroplasty

Fig. 2. Risk of bias assessment of included studies.

Fig. 3. The forest plot for pain relief at < 2 weeks.

Comparative treatments employed in the selected trials. Besides, from 3 months to 6 months, the sham injection number of the conservative group dropped or even disappeared. Pain scores were similar in the PVP and sham injection groups from 2 weeks to 6 months. There are several possible explanations for this observation. First, the local anesthesia provided as part of the sham procedure might afford a degree of medium- to long-term analgesia; local infiltration with bupivacaine may act as a nerve block to relieve pain. Second, the relatively small sample size of these 2 studies (n = 209) might have led to false negative differences between the PVP and sham injection groups (15,18). Third, the sham procedure might have a placebo effect. Finally, but the most importantly, PVP may also afford analgesia by means of a placebo response.

There were many publications which have reported the placebo response (24-29). The present evidence illustrated that the placebo effect depended on a variety of neurochemical and neurophysiological mechanisms, which were measurable and modifiable. But the placebo response was inexorably tied to the context of treatment. All medical treatments took place in a particular context, which included the therapist's attitude, psychosocial factors affecting the therapeutic relationship, and the patient's mindset. Therapeutic efficacy at least in part was attributable to the concordance between the proposed treatment and the patient's belief system. It was this fraction of the thera-
The placebo effect was commonly called the therapeutic response which was not attributable to the properties of active ingredients (24). Spontaneous improvement and effect of placebo contributed importantly to the observed treatment effect in actively treated patients, but the relative importance of these factors differed according to clinical condition and intervention (29). However, creative experimental efforts were still needed to assess rigorously the clinical significance of placebo interventions and investigate the component elements that may contributed to therapeutic benefit (28).

Conservative treatments are continuously used to treat OVCF in clinical practice. Conservative treatments include bed rest, optimum pain treatment, optimal medical therapy, and placebo treatment, et al. We think that the pain relief in the placebo treatment is different from the natural course of pain with OVCF to a certain extent. When the placebo treatment is
invasive, the remarkable pain relief could be achieved in the short-term. There may be several reasons to explain the placebo effect, such as narcotic effects, psychological effects, and neural excitatory effects (30-32). However, in the long-term, the pain relief with the placebo treatment is similar to the natural course of pain with OVCF. We will pay close attention to this issue in future.

After analysis of the data yielded from the randomized controlled research into PVP, our opinion is that PVP can reduce the amount of pain after OVCF, but that there may be an element of placebo in this benefit. The trials published in the New England Journal of Medicine were well designed (15,18), the implementation standards foresightedness findings extrapolation is high, thus the quality of evidence yielded from these reports is high. However, even these studies were relatively small, and larger studies are needed in broader patient groups and populations. If these should arrive at the same conclusion, it would imply that previous positive results are the consequence of inadequately designed studies or statistical quirks, and the dispute about the utility of PVP would be resolved.

Although PVP is generally considered to be a safe procedure, rare but serious complications may occur. The most frequent is cement leak, which may lead to spinal cord injury and varying degrees of motor or sensory nerve dysfunction (33-35). Other serious complications that have been reported include cement pulmonary embolism (36,37) and osteomyelitis in a patient with established infection (38). Since the value of PVP in the management of OVCF is still not clear, conservative treatments are still warranted and are generally still employed before the decision to undertake PVP is made. Conservative treatments might be less expensive and have fewer and less serious associated complications.
In addition, kyphoplasty is utilized commonly in clinical practice to treat OVCF as another surgical approach. However, there is also a dispute in the treatment of OVCF with kyphoplasty. A publication by Lee et al (39) reported that both kyphoplasty and conservative treatment of OVCF showed successful clinical results at the end of the one-year follow-up period and kyphoplasty showed better outcomes in the first month only. Given these results, prompt kyphoplasty should not be indicated in the case of a patient with OVCF that has no risk factors for failure with conservative treatment.

Several systematic reviews and meta-analyses have examined the utility of vertebroplasty and kyphoplasty compared with non-operative treatment (40-42). The emphasis and conclusions they drew were somewhat different from ours. Anderson and colleagues (43) conducted a systematic review of studies comparing non-operative treatment with cement augmentation using a similar methodology to ours, and reported that pain improvement was significantly greater in the cement group at all time points from 3 to 12 months although the magnitude of improvement diminished over time. Importantly, however, data from studies of percutaneous kyphoplasty (PKP) were included and there is no conclusive proof that PKP is as effective as PVP (20). Anderson et al (43) concluded that cement augmentation of OVCF conveyed a therapeutic benefit, but did not consider the placebo effect or analyze subgroups. A systematic review of non-randomized controlled research has also been conducted (44), with a different emphasis and methodology to our study. Other studies have included assessments of complications (41,42,45); however, we chose to focus on pain relief as the most important outcome measure.

**Limitations**

One limitation of our study is that there were few sources from which to extract abstracted data or published studies. There were only 5 randomized controlled trials that met our criteria. Although the risk of publication bias exists in any meta-analysis, whether based on individual patient data or not, we feel that this was not an important aspect of our study as both positive and negative trials were included. Obvious confounding variables are differences in inclusion and exclusion criteria, treatment modalities employed, and endpoints. To account for this heterogeneity a random effects model was chosen. Another limitation was that the treatments administered to patients in the comparison groups were non-uniform and varied widely; some were conservative but 2 used sham surgery controls (15,18).

**Conclusion**

In conclusion, our analysis demonstrates that there were differences in pain relief experienced by patients undergoing PVP and those managed conservatively at some time points. However, we are still not able to state which is the optimal approach and superior treatment for OVCF. Large, randomized, placebo-controlled clinical trials that compare conservative treatment with vertebroplasty over several years are needed to provide a definitive answer to the question of how best to treat OVCF.

**Acknowledgments**

This study was supported by the Natural Science Foundation of China (81102604). This study was also designed by Dr Yongjun Wang.

**References**

Comparing Pain Reduction Following Vertebroplasty


